Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/27/2011US20110263540 Small-molecule inhibitors of protein synthesis inactivating toxins
10/27/2011US20110263539 Ship 1 modulator compounds
10/27/2011US20110263537 Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion
10/27/2011US20110263536 Methods of Treating Orthopox Virus Infections and Associated Diseases
10/27/2011US20110263535 Tyrosine-based prodrugs of antiviral agents
10/27/2011US20110263534 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
10/27/2011US20110263533 Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
10/27/2011US20110263532 Halofuginone analogs for inhibition of trna synthetases and uses thereof
10/27/2011US20110263531 Methods for the treatment and amelioration of atopic dermatitis
10/27/2011US20110263530 Aurora Kinase Modulators and Method of Use
10/27/2011US20110263529 Gamma secretase modulators
10/27/2011US20110263528 Antimicrobial compositions
10/27/2011US20110263527 Sulfated Galactans With Antithrombotic Activity, Pharmaceutical Composition, Method for Treating or Prophylaxis of Arterial or Venous Thrombosis, Method of Extraction and Use Thereof
10/27/2011US20110263526 Nitric Oxide Releasing Prodrugs of Therapeutic Agents
10/27/2011US20110263525 Drug composition cytotoxic for pancreatic cancer cells
10/27/2011US20110263524 Sns-595 and methods of using the same
10/27/2011US20110263523 Tet2 as a new diagnostic and pronostic marker in hematopoietic neoplasms
10/27/2011US20110263522 Antitumour compositions containing taxane derivatives
10/27/2011US20110263521 Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
10/27/2011US20110263520 Composition for use in controlling harmful organisms that contains 16-keto aspergillimide
10/27/2011US20110263519 Regulators of the hedgehog pathway, compositions and uses related thereto
10/27/2011US20110263518 D-Tagatose-Based Compositions and Methods for Preventing and Treating Atherosclerosis, Metabolic Syndrome, and Symptoms Thereof
10/27/2011US20110263515 Capture agents and related compositions, methods and systems
10/27/2011US20110263514 Delivery of agents using interfering nanoparticles
10/27/2011US20110263498 Method and composition for enhancement of male erectile function
10/27/2011US20110263494 Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf-kappab acitivity and use thereof
10/27/2011US20110263493 Treatment for diabetes in patients inappropriate for metformin therapy
10/27/2011US20110263492 Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension of dispersion media
10/27/2011US20110263486 Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation
10/27/2011US20110263482 Complement inhibitors
10/27/2011US20110263478 Sur1 inhibitors for therapy
10/27/2011US20110262596 Carbohydrate And Electrolyte Replacement Composition
10/27/2011US20110262566 Novel useful therapeutic agent for lower urinary tract symptom
10/27/2011US20110262565 PIP-2 Inhibition-Based Antiviral and Anti-Hyperlipidemic Therapies
10/27/2011US20110262561 Protoilludance Norsesquiterpenoid Esters and Uses Thereof
10/27/2011US20110262558 Composition For Skin Sanitization And Protection And Method Of Its Use
10/27/2011US20110262556 Silver/water, silver gels and silver-based compositions; and methods for making and using the same
10/27/2011US20110262550 Method for treating a skin ailment
10/27/2011US20110262548 Novel prostaglandin e1 derivative and nanoparticle having the same encapsulated therein
10/27/2011US20110262547 Process for preparing carrier particles for dry powders for inhalation
10/27/2011US20110262546 Gold nanoparticles coated with polyelectrolytes and albumin
10/27/2011US20110262544 Ophthalmic administration of a composition including brimonidine as a mist
10/27/2011US20110262543 Process for providing particles with reduced electrostatic charges
10/27/2011US20110262542 Controlled Delivery of Tetracycline Compounds and Tetracycline Derivatives
10/27/2011US20110262540 Solid Pharmaceutical Composition Comprising Exemestane
10/27/2011US20110262539 Pharmaceutical compositions
10/27/2011US20110262538 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
10/27/2011US20110262537 Extended release dosage form of ropinirole
10/27/2011US20110262535 Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof
10/27/2011US20110262534 polysaccharide capsule enclosing a fatty acid oil-containing emulsion
10/27/2011US20110262533 Pharmaceutical formulation for use in hiv therapy
10/27/2011US20110262532 Controlled Release Hydrocodone Formulations
10/27/2011US20110262528 Pharmaceutical composition for the prevention and treatment of bone tissue resorption of various etiology
10/27/2011US20110262527 Cationic lipids and methods of use
10/27/2011US20110262525 Methods of treatment
10/27/2011US20110262524 Liposomes with improved drug retention for treatment of cancer
10/27/2011US20110262522 Transmucosal delivery devices with enhanced uptake
10/27/2011US20110262521 Medical device including bacterial cellulose reinforced by resorbable or non resorbable reinforcing materials
10/27/2011US20110262520 Layered drug delivery device
10/27/2011US20110262519 Method of improving lens rotation
10/27/2011US20110262517 Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors
10/27/2011US20110262511 Novel Uses
10/27/2011US20110262502 Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
10/27/2011US20110262500 Conjugates comprising nanoparticles coated with platinum containing compounds
10/27/2011US20110262497 Novel ezetimibe formulations
10/27/2011US20110262496 Therapeutic formulation for reduced drug side effects
10/27/2011US20110262495 Pharmaceutical emulsion compositions comprising progestogen
10/27/2011US20110262494 Low-oil pharmaceutical emulsion compositions comprising progestogen
10/27/2011US20110262491 Emulsions and methods of making nanocarriers
10/27/2011US20110262490 Polymer-agent conjugates, particles, compositions, and related methods of use
10/27/2011US20110262489 Hyaluronic acid cryogel - compositions, uses, processes for manufacturing
10/27/2011US20110262487 De Novo Anembryonic Trophoblast Vesicles and Methods of Making and Using Them
10/27/2011US20110262485 Sting (stimulator of interferon genes), a regulator of innate immune responses
10/27/2011US20110262482 Anti-viral compounds
10/27/2011US20110262471 Rab6kifl/kif20a epitope peptide and vaccines containing the same
10/27/2011US20110262469 Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax
10/27/2011US20110262465 Prostate stem cells and uses thereof
10/27/2011US20110262464 Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3
10/27/2011US20110262463 Syngr4 for target genes of cancer therapy and diagnosis
10/27/2011US20110262459 Neamine Compositions and Methods of Use Thereof
10/27/2011US20110262457 Modulation of the immune response
10/27/2011US20110262455 Treatment of proliferative disorders with a death receptor agonist
10/27/2011US20110262449 Method for the treatment of gout or pseudogout
10/27/2011US20110262447 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
10/27/2011US20110262442 Compositions for treating cns disorders
10/27/2011US20110262441 Method for selective control of helper t cell function
10/27/2011US20110262437 Use of erbb4 as a prognostic and therapeutic marker for melanoma
10/27/2011US20110262432 mutated netrin 4 proteins, fragments thereof and their uses as drugs
10/27/2011US20110262428 Treating cancer by modulating rna helicases
10/27/2011US20110262426 Methods and kits used in identifying glioblastoma
10/27/2011US20110262425 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
10/27/2011US20110262418 Composition and methods for relief of neuropathological pain
10/27/2011US20110262408 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
10/27/2011US20110262407 Treatment with alpha7 selective ligands
10/27/2011US20110262406 Compositions and methods for targeted inactivation of hiv cell surface receptors
10/27/2011US20110262398 Cardiac treatment using anti-fibrotic agents
10/27/2011US20110262397 Compounds, compositions, and methods for control of hepatitis c viral infections
10/27/2011US20110262388 Novel inhibitors
10/27/2011US20110262386 Methods of treating inflammation
10/27/2011US20110262383 Naphthalimide Dosing by N-Acetyl Transferase Genotyping
1 ... 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 ... 7860